These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 2021550)
21. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787 [TBL] [Abstract][Full Text] [Related]
22. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Ozkan H; Kaya M; Cengiz A Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813 [TBL] [Abstract][Full Text] [Related]
23. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases. Kuusela P; Haglund C; Roberts PJ; Jalanko H Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731 [TBL] [Abstract][Full Text] [Related]
24. Significance of CA 72.4 serum levels in gastrointestinal diseases. Piantino P; Taccone W; Fusaro A; Daziano E; Polloni R; Mosso R Int J Biol Markers; 1990; 5(2):77-80. PubMed ID: 2283481 [TBL] [Abstract][Full Text] [Related]
25. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Nilsson O; Johansson C; Glimelius B; Persson B; Nørgaard-Pedersen B; Andrén-Sandberg A; Lindholm L Br J Cancer; 1992 Feb; 65(2):215-21. PubMed ID: 1739620 [TBL] [Abstract][Full Text] [Related]
26. CA 72-4 compared with CEA and CA 19-9 as a marker of some gastrointestinal malignancies. Lopez JB; Royan GP; Lakhwani MN; Mahadaven M; Timor J Int J Biol Markers; 1999; 14(3):172-7. PubMed ID: 10569140 [TBL] [Abstract][Full Text] [Related]
27. Significance of CA 72-4 in colorectal carcinoma. Comparison with CEA and CA 19-9. Fernández-Fernández L; Tejero E; Tieso A Eur J Surg Oncol; 1995 Aug; 21(4):388-90. PubMed ID: 7664904 [TBL] [Abstract][Full Text] [Related]
28. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488 [TBL] [Abstract][Full Text] [Related]
29. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694 [TBL] [Abstract][Full Text] [Related]
30. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease. Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491 [TBL] [Abstract][Full Text] [Related]
32. [Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery]. Sakurai Y; Kodaira S; Teramoto T; Sugano K; Abe O; Ohtake H; Iri H Gan To Kagaku Ryoho; 1989 Sep; 16(9):3205-12. PubMed ID: 2782914 [TBL] [Abstract][Full Text] [Related]
33. [Usefulness of the determination of CA 19-9 in the follow-up of patients with gastroenteric neoplasms in comparison to CEA]. Pecchio F; Piantino P; Oliaro A; Rapellino M; Ricci E; Aimo G; Obert R Minerva Med; 1986 Nov; 77(42-43):1973-81. PubMed ID: 3464850 [TBL] [Abstract][Full Text] [Related]
34. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA. Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994 [TBL] [Abstract][Full Text] [Related]
35. Serum levels of CA 125 in patients with gastrointestinal cancers. Omar YT; al-Naqeeb N; el Nas SA; Awwad AH; Foudeh MO; Safadi NB; Nasralla MY; Ali MA; Szymendera JJ Tumour Biol; 1989; 10(6):316-23. PubMed ID: 2480631 [TBL] [Abstract][Full Text] [Related]
36. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604 [TBL] [Abstract][Full Text] [Related]
37. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700. van Dalen A; Kessler AC Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058 [TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of CA72-4, CA195 and carcinoembryonic antigen in patients with gastrointestinal malignancies. Kornek GV; Depisch D; Rosen HR; Temsch EM; Scheithauer W J Cancer Res Clin Oncol; 1992; 118(4):318-20. PubMed ID: 1374412 [TBL] [Abstract][Full Text] [Related]
39. [Clinical evaluation of the efficacy of the combined determination of serum markers CEA, CA 19.9, CA 72.4 as indexes of gastro-intestinal tract neoplasms]. Marchei P; Cifaldi L; De Benedetto A; Santini D; Manna A; Trasatti L; Marchei GG; Reale MG G Ital Oncol; 1990; 10(4):121-4. PubMed ID: 2093080 [TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. von Kleist S; Hesse Y; Kananeeh H Anticancer Res; 1996; 16(4B):2325-31. PubMed ID: 8694564 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]